fexapotide (Pending FDA Approval)

Brand and Other Names:Nymozarfex

Dosing & Uses

Benign Prostatic Hypertrophy

Pending FDA approval for benign prostatic hypertrophy (BPH)

Next:

Pharmacology

Mechanism of Action

Stimulates caspase, tumor necrosis factor, and B-cell lymphoma pathways in prostate glandular epithelial cells causing loss of cell membrane integrity, mitochondrial metabolic arrest, NRA depletion, NDA lysis and aggregation, and cell fragmentation and loss

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.